Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma
- 10 January 2016
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (2), e1-e5
- https://doi.org/10.1200/jco.2013.49.6166
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- CarfilzomibBlood, 2013
- The many faces of posterior reversible encephalopathy syndromeThe British Journal of Radiology, 2012
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaBlood, 2012
- A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or LymphomaClinical Cancer Research, 2012
- Posterior Reversible Encephalopathy Syndrome: Associated Clinical and Radiologic FindingsMayo Clinic Proceedings, 2010
- A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic MalignanciesClinical Cancer Research, 2009
- Posterior Reversible Encephalopathy Syndrome, Part 1: Fundamental Imaging and Clinical FeaturesAmerican Journal of Neuroradiology, 2008
- Reversible posterior leukoencephalopathy syndrome in cancerCurrent Oncology Reports, 2008
- Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the ProteasomeCancer Research, 2007
- Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With BortezomibJournal of Clinical Oncology, 2006